Claims for Patent: 9,399,627

Summary for Patent: 9,399,627

Title:	Substituted macrocyclic compounds having proteasome inhibitory activity
Abstract:	The disclosure provides for novel compounds which have proteasome inhibitory activity, pharmaceutical compositions made thereof, and methods of use thereof to treat various disorders, including cancer and nonmalignant tumors.
Inventor(s):	Pirrung; Michael C. (Riverside, CA)
Assignee:	The Regents of the University of California (Oakland, CA)
Application Number:	14/408,140
Patent Claims:	1. A compound having a structure of Formula II(a): ##STR00028## or a pharmaceutically acceptable salt thereof, wherein: X is NH, A.sup.1-A.sup.4 are each independently selected from hydrogen, deuterium, (C.sub.1-C.sub.6)alkyl, (C.sub.1-C.sub.6)alkenyl, (C.sub.1-C.sub.6)alkynyl, (C.sub.1-C.sub.5)hetero-alkyl, (C.sub.1-C.sub.5)hetero-alkenyl, and (C.sub.1-C.sub.5)hetero-alkynyl; A.sup.6-A.sup.8 are each independently selected from hydrogen, deuterium, hydroxyl, halo, cyano, amino, nitro, alkoxy, alkoxycarbonyl, (C.sub.1-C.sub.4)alkyl, (C.sub.1-C.sub.4)alkenyl, (C.sub.1-C.sub.4)alkynyl, (C.sub.1-C.sub.3)hetero-alkyl, (C.sub.1-C.sub.3)hetero-alkenyl, and (C.sub.1-C.sub.3)hetero-alkynyl; A.sup.12 is selected from hydrogen, deuterium, hydroxyl, halo, cyano, amino, carboxamido, carboxyl, nitro, alkoxy, alkoxycarbonyl, (C.sub.1-C.sub.8)alkyl, (C.sub.1-C.sub.8)alkenyl, (C.sub.1-C.sub.8)alkynyl, (C.sub.1-C.sub.7)hetero-alkyl, (C.sub.1-C.sub.7)hetero-alkenyl, (C.sub.1-C.sub.7)hetero-alkynyl, cycloalkyl, aryl, and heterocycle; A.sup.13 is selected from hydrogen, deuterium, hydroxyl, halo, cyano, amino, carboxamido, carboxyl, nitro, alkoxy, alkoxycarbonyl, (C.sub.1-C.sub.4)alkyl, (C.sub.1-C.sub.4)alkenyl, (C.sub.1-C.sub.4)alkynyl, (C.sub.1-C.sub.3)hetero-alkyl, (C.sub.1-C.sub.3)hetero-alkenyl, (C.sub.1-C.sub.3)hetero-alkynyl, cycloalkyl, aryl, and heterocycle; and A.sup.14 is selected from hydrogen, deuterium, (C.sub.12-C.sub.16)alkyl, (C.sub.12-C.sub.16)alkenyl, (C.sub.12-C.sub.16)alkynyl, (C.sub.12-C.sub.15)hetero-alkyl, (C.sub.12-C.sub.15)hetero-alkenyl, (C.sub.12-C.sub.15)hetero-alkynyl, cycloalkyl, aryl, and heterocycle, wherein the heteroatoms making up the hetero-alkyl, hetero-alkenyl, hetero-alkynyl, and heterocycle are selected from N, O and/or S. 2. The compound of claim 1, wherein the compound is selected from: ##STR00029## ##STR00030## ##STR00031## or a pharmaceutically acceptable salt thereof. 3. The compound of claim 1, comprising a structure of Formula II(b): ##STR00032## or a pharmaceutically acceptable salt thereof, wherein: X is NH; A.sup.14 is selected from hydrogen, deuterium, (C.sub.12-C.sub.16)alkyl, (C.sub.12-C.sub.16)alkenyl, (C.sub.12-C.sub.16)alkynyl, (C.sub.12-C.sub.15)hetero-alkyl, (C.sub.12-C.sub.15)hetero-alkenyl, (C.sub.12-C.sub.15)hetero-alkynyl, cycloalkyl, aryl, and heterocycle, wherein the heteroatoms making up the hetero-alkyl, hetero-alkenyl, hetero-alkynyl, and heterocycle are selected from N, O and/or S. 4. The compound of claim 3, wherein the compound is selected from: ##STR00033## or a pharmaceutically acceptable salt thereof. 5. A compound having the structure of: ##STR00034## or a pharmaceutically acceptable salt thereof. 6. A pharmaceutical composition comprising the compound of claim 1 and one or more pharmaceutically acceptable carriers. 7. The pharmaceutical composition of claim 6, wherein the composition is formulated to be administered intravenously or subcutaneously. 8. The pharmaceutical composition of claim 7, wherein the intravenous or subcutaneously dose comprises between 1 mg/mL to 5 mg/mL of the compound. 9. A method of treating a subject having or suspected of having a cancer comprising administering a therapeutically effective amount of the compound of claim 1 to the subject in need thereof, wherein the subject has a cancer selected from the group consisting of ovarian cancer, breast cancer, colorectal cancer, colon cancer, rectal cancer, prostate cancer, kidney or renal cancer, CNS neoplasms, neuroblastomas, glioblastomas, melanomas, non-small cell lung cancer and leukemia. 10. The method of claim 9, wherein the cancer is kidney cancer. 11. The method of claim 9, further comprising the administration of one or more additional therapeutic agents. 12. The method of claim 11, wherein the one or more additional therapeutic agents are one or more chemotherapeutic agents. 13. The method of claim 12, wherein the one or more chemotherapeutic agents is selected from cisplatin, carboplatin, vinblastine, platinum, arginine deiminase, asparaginase, thiotepa, cyclosphosphamide, busulfan, improsulfan, piposulfan, calusterone, dromostanolone propionate, epitiostanol, mepitiostane, testolactone, aminoglutethimide, mitotane, trilostane, flutamide, nilutamide, bicalutamide, leuprolide, goserelin, aclacinomysins, actinomycin, authramycin, azaserine, bleomycins, cactinomycin, calicheamicin, carabicin, caminomycin, carzinophilin, chromomycins, dactinomycin, daunorubicin, detorubicin, 6-diazo-5-oxo-L-norleucine, doxorubicin, epirubicin, esorubicin, idarubicin, marcellomycin, mitomycins, mycophenolic acid, nogalamycin, olivomycins, peplomycin, potfiromycin, puromycin, quelamycin, rodorubicin, streptonigrin, streptozocin, tubercidin, ubenimex, zinostatin, zorubicin, tamoxifen, raloxifene, 4-hydroxytamoxifen, trioxifene, keoxifene, LY 117018, onapristone, toremifene, methotrexate, 5-fluorouracil, denopterin, methotrexate, pteropterin, trimetrexate, benzodopa, carboquone, meturedopa, uredopa, ethylenimines, altretamine, triethylenemelamine, trietylenephosphoramide, triethylenethiophosphaoramide, trimethylolomelamine, frolinic acid, chlorambucil, chlornaphazine, cholophosphamide, estramustine, ifosfamide, mechlorethamine, mechlorethamine oxide hydrochloride, melphalan, novembichin, phenesterine, prednimustine, trofosfamide, uracil mustard, carmustine, chlorozotocin, fotemustine, lomustine, nimustine, ranimustine, fludarabine, 6-mercaptopurine, thiamiprine, thioguanine, ancitabine, azacitidine, 6-azauridine, carmofur, cytarabine, dideoxyuridine, doxifluridine, enocitabine, floxuridine, paclitaxel, docetaxel, RFS 2000, thymidylate synthase inhibitors, aceglatone, aldophosphamide glycoside, aminolevulinic acid, amsacrine, bestrabucil, bisantrene, edatraxate, defofamine, demecolcine, diaziquone, difluoromethylornithine (DMFO), elformithine, elliptinium acetate, etoglucid, gallium nitrate, hydroxyurea, lentinan, lonidamine, mitoguazone, mitoxantrone, mopidamol, nitracrine, pentostatin, phenamet, pirarubicin, podophyllinic acid, 2-ethylhydrazide, procarbazine, razoxane, sizofuran, spirogermanium, tenuazonic acid, triaziquone, 2,2',2''-trichlorotriethylamine, urethane, vindesine, dacarbazine, mannomustine, mitobronitol, mitolactol, pipobroman, gacyto sine, arabinoside ("Ara-C"), chlorambucil, gemcitabine, 6-thioguanine, mercaptopurine, methotrexate, etoposide, ifosfamide, mitomycin C, mitoxantrone, vincristine, vinorelbine, navelbine, novantrone, teniposide, daunomycin, aminopterin, xeloda, ibandronate, CPT-11, retinoic acid, esperamicins, and capecitabine. 14. The method of claim 12, wherein the one or more chemotherapeutic agents is selected from vinblastine, floxuridine, 5-fluorouracil, capecitabine, gemcitabine, bortezomib, cyclophosphamide, melphalan, doxorubicin, idarubicin, cisplatin, etoposide, and bendamustine. 15. The compound of claim 1, wherein the compound has a structure of Formula II(a): ##STR00035## or a pharmaceutically acceptable salt thereof, wherein: X is NH; A.sup.1-A.sup.4, A.sup.6-A.sup.8, A.sup.12 are hydrogen; A.sup.13 is a 1-hydroxyethyl group; and A.sup.14 is a (C.sub.12-C.sub.16)alkenyl group.

Details for Patent 9,399,627

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Recordati Rare Diseases, Inc.	ELSPAR	asparaginase	For Injection	101063	01/10/1978		2032-06-15